Patient P-01490

Synthetic patientNBL-101 · Day 91 · 65–74 · F · baseline S05Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

39%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S05
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 SC-12 recommended — Supportive Compound SC-12
Day 53 Patient accepted — Started SC-12 in the companion
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient accepted — Started GI-04 in the companion
Day 57 ME-01 recommended — Monitoring Escalation ME-01
Day 58 Patient accepted — Started ME-01 in the companion
Day 59 GI symptom burden −22% vs expected — Supportive Compound SC-12
Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 63 GI symptom burden −22% vs expected — GI Support Protocol GI-04
Day 65 Tolerance state changed — Unstable → Improving
Day 69 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Inflammatory activity-17
GI instability-15
Treatment adherence-6
Nutritional resilience+3

What helped?

Supportive Compound SC-12Day 52
Result: symptom burden −22%
GI Support Protocol GI-04Day 54
Result: symptom burden −22%
Monitoring Escalation ME-01Day 57
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Adherence Support AD-05

30%

probability of meaningful tolerance improvement

284 similar trajectories
25% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 28/100
- MicrobiomeF. prausnitzii depleted
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 41
Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 24 ms, trending down
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Autonomic recovery ↑20
- Wearable3,343 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 3.1 · butyrate capacity 28/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 24 ms
Sleep: 7.1 h
Steps: 2,638
Resting HR: 70 bpm

Daily log: GI score 28, nutritional resilience 54, adherence 58.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01663	47%	S14	GI-04	improved	48
P-01574	46%	S14	GI-04	improved	47
P-01568	43%	S14	GI-04	improved	40
P-01323	42%	S14	GI-04	improved	50
P-01325	42%	S16	GI-04	improved	54
P-01667	41%	S10	GI-04	improved	49
P-01534	40%	S14	GI-04	improved	50
P-01649	39%	S14	GI-04	improved	46
P-01501	38%	S14	GI-04	improved	45
P-01635	38%	S02	GI-04	improved	49
P-01688	38%	S01	GI-04	improved	40
P-01337	37%	S14	GI-04	improved	53